Phase 3 study of itepekimab (anti-IL-33 mAb) in moderate-to-severe COPD
Chronic Obstructive Pulmonary Disease
Enrolment: 1127 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Chronic Obstructive Pulmonary Disease
Enrolment: 1127 · Results not recorded
Viral Lung Infection and Acute Respiratory Failure
Enrolment: 3527 · Results not recorded
Chronic Obstructive Pulmonary Disease
Enrolment: 49 · Results not recorded
Chronic Obstructive Pulmonary Disease (COPD) · Chronic Bronchitis
Enrolment: 137 · Results not recorded
Healthy Participants
Enrolment: 254 · Results not recorded
Acute Pancreatitis
Enrolment: 44 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Experimental colitis induced by intrarectal 2,4,6-trinitrobenzene sulphonic acid (150 mg/kg) or by 3% dextran sodium sulphate in drinking water for 7 days, plus endoscopic biopsy-induced acute mechanical mucosal wounding of the descending colon
Genetic ablation of ST2 or IL-33 and treatment with a neutralising anti-ST2 antibody reduced disease activity, histological damage and colonic IL-6 and improved mucosal wound healing, whereas exogenous recombinant IL-33 worsened colitis and increased intestinal permeability.
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.